Short Interest in Autonomix Medical, Inc. (NASDAQ:AMIX) Drops By 29.7%

Posted by Anthony Miller on Mar 5th, 2025

Autonomix Medical, Inc. (NASDAQ:AMIX – Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 99,700 shares, a decrease of 29.7% from the January 31st total of 141,900 shares. Based on an average daily volume of 377,400 shares, the short-interest ratio is presently 0.3 days. Approximately 8.0% of the company’s shares are short sold.

Autonomix Medical Stock Up 3.8 %

Shares of AMIX opened at $2.47 on Wednesday. The firm has a market cap of $6.08 million and a PE ratio of -0.19. The company’s fifty day moving average is $2.97 and its two-hundred day moving average is $7.79. Autonomix Medical has a fifty-two week low of $2.24 and a fifty-two week high of $82.00.

Autonomix Medical (NASDAQ:AMIX – Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.46) earnings per share for the quarter. As a group, equities research analysts anticipate that Autonomix Medical will post -10 earnings per share for the current year.

Institutional Trading of Autonomix Medical

A hedge fund recently bought a new stake in Autonomix Medical stock. Citadel Advisors LLC acquired a new stake in shares of Autonomix Medical, Inc. (NASDAQ:AMIX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 47,884 shares of the company’s stock, valued at approximately $180,000. Citadel Advisors LLC owned 4.16% of Autonomix Medical as of its most recent SEC filing. 10.78% of the stock is owned by hedge funds and other institutional investors.

Autonomix Medical Company Profile

(Get Free Report)

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.